Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjoy K Paul

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Diabetes Care|January 26, 2019
Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective TherapiesOlga Montvida, Xiaoling Cai, Sanjoy K Paul
European Heart Journal|December 8, 2020
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world studySanjoy K Paul, Deepak L Bhatt, Olga Montvida
Journal of Healthcare Informatics Research|February 6, 2023
Robustness of Multiple Imputation Methods for Missing Risk Factor Data from Electronic Medical Records for Observational StudiesSanjoy K Paul, Joanna Ling, Mayukh Samanta, et al.
Journal of Diabetes|May 2, 2015
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetesSanjoy K Paul, Kerenaftali Klein, Azeem Majeed, et al.
Diabetes Care|June 14, 2022
Cardiorenal Complications in Young-Onset Type 2 Diabetes Compared Between White Americans and African AmericansSanjoy K Paul, Jonathan E Shaw, Peter Fenici, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world studyOlga Montvida, Subodh Verma, Jonathan E Shaw, et al.
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
Diabetes, Obesity & Metabolism|March 15, 2018
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world studyOlga Montvida, Jonathan E Shaw, Lawrence Blonde, et al.
Acta Diabetologica|September 1, 2018
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality riskEbenezer S Owusu Adjah, Kausik K Ray, Sanjoy K Paul
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Diabetes Care|January 26, 2019
Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective TherapiesOlga Montvida, Xiaoling Cai, Sanjoy K Paul
European Heart Journal|December 8, 2020
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world studySanjoy K Paul, Deepak L Bhatt, Olga Montvida
Journal of Healthcare Informatics Research|February 6, 2023
Robustness of Multiple Imputation Methods for Missing Risk Factor Data from Electronic Medical Records for Observational StudiesSanjoy K Paul, Joanna Ling, Mayukh Samanta, et al.
Journal of Diabetes|May 2, 2015
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetesSanjoy K Paul, Kerenaftali Klein, Azeem Majeed, et al.
Diabetes Care|June 14, 2022
Cardiorenal Complications in Young-Onset Type 2 Diabetes Compared Between White Americans and African AmericansSanjoy K Paul, Jonathan E Shaw, Peter Fenici, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world studyOlga Montvida, Subodh Verma, Jonathan E Shaw, et al.
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
Diabetes, Obesity & Metabolism|March 15, 2018
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world studyOlga Montvida, Jonathan E Shaw, Lawrence Blonde, et al.
Acta Diabetologica|September 1, 2018
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality riskEbenezer S Owusu Adjah, Kausik K Ray, Sanjoy K Paul
Pageof 7